Literature DB >> 2413739

Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs.

N Chand, J Pillar, W Diamantis, R D Sofia.   

Abstract

The ability of azelastine to inhibit IgE-mediated allergic histamine release from the peritoneal mast cells of actively sensitized rats was investigated and compared with selected antiallergic agents. Azelastine added simultaneously with the allergic stimuli (ovalbumin, OA, 10 micrograms/ml + phosphatidylserine, PS, 10 micrograms/ml) or preincubated with cells for 10 min prior to antigen challenge produced similar concentration-dependent inhibition of allergic histamine release. The IC50s (microM) following 10-min preincubation were as follows: azelastine = 4.8; astemizole = 86.3; ketotifen = 112.2; diphenhydramine = 133 and theophylline = 2040.3. At IC50 level azelastine was about 18, 23, 28 and 425 times as effective as astemizole, ketotifen (newer histamine H1-receptor antagonists), diphenhydramine (a traditional H1-receptor antagonist), and theophylline (a phosphodiesterase inhibitor), respectively. Sodium cromoglycate in a concentration range or 1-1000 microM (0 or 10-min preincubation) failed to exert any inhibitory effect. These data showed that among six drugs tested azelastine is the most potent inhibitor of allergic histamine release from rat peritoneal mast cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413739     DOI: 10.1007/bf01982866

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  THE MECHANISM OF ANAPHYLAXIS. I. PRODUCTION AND BIOLOGICAL PROPERTIES OF 'MAST CELL SENSITIZING' ANTIBODY.

Authors:  I MOTA
Journal:  Immunology       Date:  1964-11       Impact factor: 7.397

2.  A method for the fluorometric assay of histamine in tissues.

Authors:  P A SHORE; A BURKHALTER; V H COHN
Journal:  J Pharmacol Exp Ther       Date:  1959-11       Impact factor: 4.030

3.  Anti-allergic effect of azelastine hydrochloride on immediate type hypersensitivity reactions in vivo and in vitro.

Authors:  S Katayama; N Akimoto; H Shionoya; T Morimoto; Y Katoh
Journal:  Arzneimittelforschung       Date:  1981

4.  Pharmacological and toxicological properties of azelastine, a novel antiallergic agent.

Authors:  H J Zechel; N Brock; D Lenke; U Achterrath-Tuckermann
Journal:  Arzneimittelforschung       Date:  1981

Review 5.  The pharmacological control of immediate hypersensitivity.

Authors:  J C Foreman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

6.  Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells.

Authors:  B Fischer; W Schmutzler
Journal:  Arzneimittelforschung       Date:  1981

7.  Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells.

Authors:  D A Fields; J Pillar; W Diamantis; J L Perhach; R D Sofia; N Chand
Journal:  J Allergy Clin Immunol       Date:  1984-03       Impact factor: 10.793

8.  Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action.

Authors:  N Chand; J Pillar; W Diamantis; J L Perhach; R D Sofia
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

9.  STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN.

Authors:  L M LICHTENSTEIN; A G OSLER
Journal:  J Exp Med       Date:  1964-10-01       Impact factor: 14.307

  9 in total
  13 in total

Review 1.  Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.

Authors:  Gyan P Mishra; Viral Tamboli; Jwala Jwala; Ashim K Mitra
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2011-01

2.  Azelastine inhibits bronchial hyperreactivity to acetylcholine in guinea pigs.

Authors:  U Achterrath-Tuckermann; I Szelenyi
Journal:  Experientia       Date:  1988-12-01

3.  The effect of azelastine and some other antiasthmatic and antiallergic drugs on calmodulin and protein kinase C.

Authors:  E Middleton; P Ferriola; G Drzewiecki; R D Sofia
Journal:  Agents Actions       Date:  1989-08

Review 4.  Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 5.  Heterogeneity of calcium channels in mast cells and basophils and the possible relevance to pathophysiology of lung diseases: a review.

Authors:  N Chand; J L Perhach; W Diamantis; R D Sofia
Journal:  Agents Actions       Date:  1986-03

6.  Modulation of in vitro anaphylaxis of guinea-pig isolated tracheal segments by azelastine, inhibitors of arachidonic acid metabolism and selected antiallergic drugs.

Authors:  N Chand; W Diamantis; R D Sofia
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

7.  Influence of epithelial removal on the antihistaminic activity of azelastine in the guinea-pig airway smooth muscles.

Authors:  Y Kamikawa
Journal:  Agents Actions       Date:  1993-11

8.  Effect of azelastine on sulphur dioxide induced impairment of ciliary motility in airway epithelium.

Authors:  J Tamaoki; A Chiyotani; N Sakai; K Takeyama; K Konno
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

9.  Azelastine and allergen transduction signal in MC9 mast cells.

Authors:  K Fanous; R P Garay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

Review 10.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.